Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Two Drug Companies Establish New Labs
by Rick Mullin
April 20, 2015
| A version of this story appeared in
Volume 93, Issue 16
Cellectis, a Paris-based gene-editing specialist focused on chimeric antigen receptor T-cell (CART) cancer therapies, has established a U.S. subsidiary at the Alexandria Center for Life Science in New York City. The company will occupy 12,000 sq ft of laboratory space at the center, which was launched in 2011 to attract life sciences research to the city. Meanwhile, the Delaware-based biotech firm Incyte will establish a European headquarters in Geneva. The firm will conduct clinical development operations in a 9,000-sq-ft research facility.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter